Key result
A case vignette of a 68-year-old male with ischemic heart disease is presented to support the use of vasodilator therapy in acute heart failure.
Why the study?
Do vasodilators remain an indispensable treatment for acute heart failure?
Case Report (n=1)
Do vasodilators remain an indispensable treatment for acute heart failure?
This article presents a pro-con debate on the role of vasodilator therapy in acute heart failure, introduced via a clinical case vignette.
Vasodilator therapy in acute heart failure 851 Case vignette M. is a 68-year-old male with ischaemic heart disease who presented 16 months ago with an inferolateral myocardial infarction due to an occluded circumflex artery for which he received urgent percutaneous intervention with successful placement of a drug-eluting stent. No other significant coronary lesions were visualized at that time. Left ventricular (LV) ejection fraction after discharge was 45% with persistent inferolateral hypo to akinesia and moderate secondary mitral valve regurgitation. Medical history is notable for diabetes, hypertension, and chronic kidney disease Stage IIIB.
No takes yet. Share an insight, caveat, or question.
Vanhentenrijk et al. (2022) conducted a case report in Acute heart failure (n=1). Vasodilator therapy was evaluated. A case vignette of a 68-year-old male with ischemic heart disease is presented to support the use of vasodilator therapy in acute heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: